| Popis: |
Pharmaceutical M&As in emerging markets may jeopardize cheap access to generics. This may be a motivation for policy makers to use competition law as a tool to deter cross-border M&As. Additionally, while M&As in the pharmaceutical sector may give rise to certain efficiencies, it is not clear how efficiencies will be treated in the peculiar socio-economic context of emerging markets. This article develops a theoretical framework that argues that the application of competition law is guided by sector-specific socio-economic realities and institutional realities of the jurisdiction. Thereafter, it employs this framework to analyze the issues of access to generics and efficiencies of production. |
